Favorable longterm outcomes of liver transplant recipients treated de novo with once‐daily tacrolimus: Results of a single‐center cohort

Mikel Gastaca, Andrés Valdivieso, Javier Bustamante, José R. Fernández, Patricia Ruiz, Alberto Ventoso, Milagros Testillano, Ibone Palomares, Patricia Salvador, Mikel Prieto, Miguel Montejo, María J. Suárez, Jorge Ortiz de Urbina – 19 July 2016 – The once‐daily prolonged‐release formulation of tacrolimus has been recently related with significant graft and patient mid‐term survival advantages; however, practical information on the de novo administration after liver transplantation and longterm outcomes is currently lacking.

Hepatic encephalopathy expands the predictivity of model for end‐stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts

Cristina Lucidi, Stefano Ginanni Corradini, Juan G. Abraldes, Manuela Merli, Puneeta Tandon, Flaminia Ferri, Lucia Parlati, Barbara Lattanzi, Edoardo Poli, Vincenza Di Gregorio, Alessio Farcomeni, Oliviero Riggio – 19 July 2016 – Despite its documented prognostic relevance, hepatic encephalopathy (HE) is not considered in liver transplantation (LT) due to its possible poor objectivity. To override this problem, we aimed to analyze if an objective diagnosis of HE may confer additional mortality risk beyond MELD.

Subscribe to